ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference in New York, NY. The presentation is scheduled for June 7, 2023 at 9:00 am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005184/en/

INVESTOR RELATIONS
ImmunoGen
Anabel Chan
781-895-0600
[email protected]

MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
[email protected]

OR

FTI Consulting
Robert Stanislaro
212-850-5657
[email protected]

Source: ImmunoGen, Inc.

You May Also Be Interested In

• Southwest Bancshares, Inc., Announces Texas Partners Bank as the Regional Bank Brand
• POWERFLEET ALERT: Bragar Eagel & Squire, P.C. is Investigating PowerFleet, Inc. on Behalf of PowerFleet Stockholders and Encourages Investors to Contact the Firm
• Grand Peak Closes Non-Brokered Private Placement